Allison W. Kurian, M.D., M.Sc.
Academic Appointments
- Assistant Professor - Med Center Line, Medicine - Oncology
- Assistant Professor - Med Center Line, Health Research & Policy
- Member, Cancer Center
Contact Information
-
Clinical Offices
Oncology 875 Blake Wilbur Dr MC 5826 Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 498-5150
- Academic Offices
Administrative Contact Oncology Clinic Tel Work 650-498-6000Not for medical emergencies or patient use
Professional Snapshot
Clinical Focus
- Cancer > Breast Cancer
- Cancer Genetics
- Medical Oncology
- Breast Cancer Risk
Administrative Appointments
- Associate Director, Stanford Clinical Cancer Genetics Program (2007 - present)
- Member, Career Development Subcommittee, American Society of Clinical Oncology (2008 - 2011)
- Member, Professional Development Annual Meeting Track Team, American Society of Clinical Oncology (2009 - 2011)
- Member, Panel on Clinical Guideline Development for Genetic Risk of Breast and Ovarian Cancer, National Comprehensive Cancer Network (2009 - present)
Honors and Awards
- Jan Weimer Faculty Investigator Award for Breast Cancer Research, Stanford University (2008)
- Physician Faculty Scholars Award, Robert Wood Johnson Foundation (2008)
- Cornelius L. Hopper Research Abstract Award, California Breast Cancer Research Program (2007)
- BIRCWH K12 Scholar Award, National Institutes of Health (2006)
- Young Investigator Award, American Society of Clinical Oncology (2005)
Professional Education
| Residency: | Massachusetts General Hospital, MA (2002) |
| Internship: | Massachusetts General Hospital, MA (2000) |
| B.A., Honors: | Stanford University, Human Biology (1995) |
| Medical Education: | Harvard Medical School, MA (1999) |
| M.D.: | Harvard Medical School, Medicine (1999) |
Community & International Work
Scientific Focus
Research Interests
My research focuses on identification of groups at elevated risk for breast and gynecologic cancers, and on development and evaluation of techniques for early cancer detection and risk reduction. This work is highly collaborative within the Divisions of Oncology and Epidemiology, with the Departments of Radiology, Obstetrics and Gynecology, and Pathology, and with the Northern California Cancer Center.
Ongoing projects include studies of racial/ethnic differences in hereditary breast and ovarian cancer, early-phase breast cancer chemoprevention and treatment trials, and computer-based simulation modeling to evaluate new approaches to cancer screening and prevention.
Clinical Trials
- Phase II Gemcitabine, Carboplatin & PARP Inhibitor BSI-201 in Neoadjuvant Tx of Triple-Neg Breast CA Recruiting
- Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Recruiting
- Phase II Trial - Breast Cancer Chemoprevention by Lovastatin Recruiting
Publications
- Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst. 2009; (15): 1058-65
- Performance of BRCA1/2 mutation prediction models in Asian Americans. J Clin Oncol. 2008; (29): 4752-8
- A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007; (6): 634-41
- Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA. 2006; (20): 2374-84
- Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol. 2005; (2): 520-30
Help